In addition, Xlife Sciences is investing in market-making and research activities to further enhance the visibility and tradability of its shares. The segment change is planned for the first quarter of 2026.

Oliver R. Baumann, CEO of Xlife Sciences AG, stated: «Transitioning to the main segment of SIX is the next logical step for Xlife Sciences: it increases visibility, improves the liquidity of our shares, and provides additional access to institutional investors. In parallel, we are intensifying efforts in market-making and research coverage to further enhance the attractiveness for existing and new shareholders.»

Financial calendar